SCHEMBL11367640

SCHEMBL11367640

COc1ccc2c(c1)c1ccccc1c1cc(-c3ccc(-c4cc5c6ccccc6c6cc(OC)ccc6c5c5ccccc45)cc3)c3ccccc3c21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACA Q13085 1/20 0.48
▸ KDM4E B2RXH2 6/20 0.47
▸ ALDH1A1 P00352 6/20 0.47
▸ HPGD P15428 5/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ ABL1 P00519 1/20 0.46
▸ ABCB1 P08183 1/20 0.46
▸ BCR P11274 1/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ PIN1 Q13526 1/20 0.45
▸ MAPT P10636 5/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ L3MBTL1 Q9Y468 3/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HTT P42858 1/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12646378 0.84 MAPT (0.46) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL13070418 0.84 MAPT (0.53) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL12126776 0.83 KDM4E (0.54) ACACAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL12128798 0.83 ACACA (0.54) ACACAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL16108132 0.82 MAPT (0.52) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL11428648 0.82 GSTP1 (0.50) ACACAL3MBTL1TSHRNPC1RAB9A
SCHEMBL12011504 0.82 CYP11B2 (0.46) ACACAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL17536913 0.82 MAPT (0.59) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL1615040 0.82 MAPT (0.59) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL2021618 0.82 MAPT (0.59) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222637-B2 Benzochrysene derivative and organic electroluminescence device using the same IDEMITSU KOSAN CO., LTD. (JP) 2012-07-17 — — US disclosed
US-20100320451-A1 BENZOCHRYSENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME IDEMITSU KOSAN CO., LTD. 2010-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100320451-A1 BENZOCHRYSENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME NRAS, KSR1, RSU1 ACACA 2715/4885KDM4E 1494/4885ALDH1A1 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback